PATH Study: Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia

This research study is to determine the safety and tolerability of pomalidomide for the treatment of HHT; to determine if pomalidomide treatment improves quality of life in HHT; to determine whether a continued response to pomalidomide is evident 12 weeks after treatment discontinuation; to develop a biorepository for future studies to define biomarkers predictive of pomalidomide response and allow investigations into the biology of HHT and mechanisms of pomalidomide

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Hereditary Hemorrhagic Telangiectasia
• Age: Between 18 Years - 99 Years
• Gender: All